Ep 38. Is risankizumab safe and effective for active psoriatic arthritis? Results from the KEEPsAKE 2 study

Talking Rheumatology Research

Dr Andrew Östör joins Dr Marwan Bukhari to discuss their article, chosen as the June Editor's Choice article, which evaluates the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR).

Listen now to hear the findings and what this means for future clinical practice!

You can read this article [https://doi.org/10.1093/rheumatology/keac605] in Rheumatology.

The countdown to #BSR25 begins!
Our full Annual Conference 2025 programme is now available. Browse 100+ sessions and get ready for an inspiring event.
https://bit.ly/4bGFX1N

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.